Literature DB >> 9669213

Inhibitory effect of somatostatin on human T lymphocytes proliferation.

C Casnici1, D Lattuada, C Perego, P Franco, O Marelli.   

Abstract

Somatostatin (SOM) was originally described as a growth hormone release inhibiting factor, but SOM and its specific receptors (SOM-r) have been shown to be expressed on both normal and activated T and B lymphocytes and other immunocompetent cells. In the present study we have demonstrated that SOM strongly inhibits the proliferation of human T lymphocytes when stimulated by PHA, Con A or alloantigens. However, SOM was most effective when the T cells were stimulated by an alloantigen rather than a polyclonal activator such as PHA and ConA. Moreover, SOM strongly inhibited the expression of activation markers such as CD69 and CD25 that are expressed on T lymphocytes during alloantigen stimulation. SOM also inhibited both CD28 and CD2 mediated T cell proliferation. Whereas proliferation of T cells induced by the engagement of CD3 antigen using specific mAbs was only marginally affected. Our results would support the concept that in humans SOM plays a key role in the modulation of T cell activation by interfering with the antigen-independent pathways CD2 and CD28.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9669213     DOI: 10.1016/s0192-0561(97)00033-7

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  3 in total

1.  Anti-inflammatory Effect of Somatostatin Analogue Octreotide on Rheumatoid Arthritis Synoviocytes.

Authors:  Claudia Casnici; Donatella Lattuada; Katia Crotta; Marcello Claudio Truzzi; Costantino Corradini; Francesca Ingegnoli; Noemi Tonna; Fabio Bianco; Ornella Marelli
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

2.  Effects of AP‑1 and NF‑κB inhibitors on colonic endocrine cells in rats with TNBS‑induced colitis.

Authors:  Magdy El-Salhy; Kazuo Umezawa
Journal:  Mol Med Rep       Date:  2016-06-27       Impact factor: 2.952

Review 3.  Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.

Authors:  Magdy El-Salhy; Tefera Solomon; Trygve Hausken; Odd Helge Gilja; Jan Gunnar Hatlebakk
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.